Handbook of anticancer pharmacokinetics and pharmacodynamics

著者

    • Figg, William D.
    • McLeod, Howard L.

書誌事項

Handbook of anticancer pharmacokinetics and pharmacodynamics

edited by William D. Figg and Howard L. McLeod

(Cancer drug discovery and development)

Humana Press, c2004

  • : E-ISBN

大学図書館所蔵 件 / 3

この図書・雑誌をさがす

注記

System requirements for accompanying disk: Adobe Acrobat reader 6.0 or later

Includes bibliographies and index

内容説明・目次

巻冊次

ISBN 9781588291776

内容説明

Leading investigators synthesize the entire laboratory and clinical process of developing anticancer drugs to create a single indispensable reference that covers all the steps from the identification of cancer-specific targets to phase III clinical trials. These expert authors provide their best guidance on a wide variety of issues, including clinical trial design, preclinical screening, and the development and validation of bioanalytic methods. The chapters on identifying agents to test in phase III trials and on trial design for the approval of new anticancer agents offer a unique roadmap for moving an agent to NDA submission.

目次

Molecular Targets Udai Banerji, Ian Judson, and Paul Workman Preclinical Screening for New Anticancer Agents Angelika M. Burger and Heinz-Herbert Fiebig Mouse Models in Cancer Drug Discovery and Development Edward A. Sausville and Melinda Hollingshead Defining the Starting Dose: Should It Be Based on mg/kg, mg/m2, or Fixed? Howard Gurney Phase I Trials in Oncology: Design and Endpoints James Cassidy Analytical Methods: Development, Validation, and Clinical Applicability Hans Ehrsson, Staffan Eksborg, and Jonas Bergh Validation and Control of Bioanalytical Methods in Clinical Drug Development H. Thomas Karnes Clinical Pharmacology Overview Andrew P. Beelen and Lionel D. Lewis Pharmacokinetic Modeling Sharyn D. Baker and Michelle A. Rudek Pharmacodynamic Modeling Kenneth S. Bauer and William P. Petros Pharmacometric Knowledge-Based Oncology Drug Development Paul J. Williams, James A. Uchizono, and Ene I. Ette Protein Binding of Anticancer Drugs Alex Sparreboom and Walter J. Loos Metabolism (Non-CYP Enzymes) Sally A. Coulthard and Alan V. Boddy Cytochrome P450 and Anticancer Drugs Yuichi Ando Polymorphisms in Genes of Drug Targets and Metabolism and in DNA Repair Jan Stoehlmacher, Syma Iqbal, and Heinz-Josef Lenz Drug Interactions, Laurent P. Rivory ABC Transporters: Involvement in Multidrug Resistance and Drug Disposition Susan E. Bates and Tito Fojo Intrathecal Chemotherapy Jeff Stone and Susan M. Blaney Use of Microdialysis in Preclinical and Clinical Development of Anticancer Agents William C. Zamboni Regional Therapy of Cancer Using Continuous Hyperthermic Peritoneal Perfusion or Vascular Isolation and Perfusion Techniques H. Richard Alexander, Maihgan A. Kavanagh, Steven K. Libutti, and James F. Pingpank Isolated Lung Perfusion for the Treatment of Inoperable Pulmonary Malignancies David S. Schrump Pharmacokinetics of Isolated Lung Perfusion with Antitumor Agents Suoping Zhai Central Nervous System Malignancy and Clinical Pharmacology Steve Y. Cho and Howard A. Fine Pharmacokinetics of Anticancer Drugs in Children Lisa C. Iacono, P. Kellie Turner, and Clinton F. Stewart Clinical Pharmacokinetics in the Elderly Patricia W. Slattum and Jurgen Venitz The Combination of Angiogenesis Inhibitors and Radiotherapy for the Treatment of Primary Tumors Kevin Camphausen and Cynthia Menard Gene Therapy for the Treatment of Cancer H. Trent Spencer and Jacques Galipeau Vaccines for the Treatment of Cancer Philip M. Arlen, James Gulley, Lauretta Odogwu, and John L. Marshall Pharmacokinetics of Antibodies and Immunotoxins in Mice and Humans Victor Ghetie, E. Sally Ward, and Ellen S. Vitetta Pharmacokinetics of Biologicals Hakan Mellstedt, Jan-Erik Frodin, and Anders Osterborg Exposure-Response Relationship of Anticancer Agents: A Clinical Pharmacology and Biopharmaceutics Regulatory Perspective Atiqur Rahman Identifying Agents to Test in Phase III Trials Thomas G. Roberts Jr., Thomas J. Lynch Jr., and Bruce A. Chabner Clinical Trial Designs for Approval of New Anticancer Agents: A Clinical Science Daniel D. Von Hoff Pharmacogenetic Counseling Jill M. Kolesar Index
巻冊次

: E-ISBN ISBN 9781592597345

内容説明

Leading investigators synthesize the entire laboratory and clinical process of developing anticancer drugs to create a single indispensable reference that covers all the steps from the identification of cancer-specific targets to phase III clinical trials. These expert authors provide their best guidance on a wide variety of issues, including clinical trial design, preclinical screening, and the development and validation of bioanalytic methods. The chapters on identifying agents to test in phase III trials and on trial design for the approval of new anticancer agents offer a unique roadmap for moving an agent to NDA submission.

目次

  • 1 Molecular Targets Udai Banerji, Ian Judson and Paul Workman
  • 2 Preclinical Screening for New Anticancer Agents Angelika M. Burger and Heinz-Herbert Fiebig
  • 3 Mouse Models in Cancer Drug Discovery and Development Edward A. Sausville and Melinda Hollingshead
  • 4 Defining the starting dose: Should it be based on mg/kg, mg/m2, or fixed? Howard Gurney
  • 5 Phase I Trials in Oncology: Design and Endpoints James Cassidy
  • 6 Analytical Methods: Development, Validation and Clinical Applicability Hans Ehrsson, Staffan Eksborg and Jonas Bergh
  • 7 Validation and Control of Bioanalytical Methods in Clinical Drug Development H. Thomas Karnes
  • 8 Clinical Pharmacology Overview Andrew P. Beelen and Lionel D. Lewis
  • 9 Pharmacokinetic Modeling Sharyn D. Baker and Michelle A. Rudek
  • 10 Pharmacodynamic Modeling Kenneth S. Bauer and William P. Petros
  • 11 Pharmacometric Knowledge-Based Oncology Drug Development Paul J. Williams, James Uchizono and Ene I. Ette
  • 12 Protein Binding of Anticancer Drugs Alex Sparreboom and Walter J. Loos
  • 13 Metabolism (Non-CYP Enzymes) Sally A. Coulthard and Alan V. Boddy
  • 14 Cytochrome P450 and anticancer drugs Yuichi Ando
  • 15 Polymorphisms in genes of drug targets and metabolism and in DNA Repair Jan Stoehlmacher, Syma Iqbal and Heinz-Josef Lenz
  • 16 Drug Interactions Laurent P. Rivory
  • 17 ABC Transporters: Involvement in Multidrug Resistance and Drug Disposition Susan E. Bates and Tito Fojo
  • 18 Intrathecal Chemotherapy Jeff Stone and Susan M. Blaney
  • 19 Use of Microdialysis in Preclinical and Clinical Development of Anticancer Agents William C. Zamboni
  • 20 Regional Therapy of Cancer Using Continuous Hyperthermic Peritoneal Perfusion or Vascular Isolation and Perfusion Techniques H. Richard Alexander, Maihgan A. Kavanagh, Steven K. Libutti, and James F. Pingpank
  • 21 Isolated Lung Perfusion for the Treatment of Inoperable Pulmonary Malignancies David S. Schrump
  • 22 Pharmacokinetics of Isolated Lung Perfusion with Antitumor Agents Suoping Zhal
  • 23 Central Nervous System Malignancy and Clinical Pharmacology Howard A. Fine and Steve Y. Cho
  • 24 Pharmacokinetics of Anticancer Drugs in Children Lisa C. Iacono, P. Kellie Turner, and Clinton F. Stewart
  • 25 Clinical Pharmacokinetics in the Elderly Patricia W. Slattum and Jurgen Venitz
  • 26 The Combination of Angiogenesis Inhibitors and Radiotherapy for the Treatment of Primary Tumors Kevin Camphausen and Cynthia Menard
  • 27 Gene Therapy for the Treatment of Cancer H. Trent Spencer and Jacques Galipeau
  • 28 Vaccines for the Treatment of Cancer Lauretta Odogwu, James Gulley, Philip M. Arlen, and John L. Marshall
  • 29 Pharmacokinetics of Antibodies and Immunotoxins in Mice and Humans Victor Ghetie, E. Sally Ward, and Ellen S. Vitetta
  • 30 Pharmacokinetics of Biologicals Hakan Mellstedt, Jan-Erik Frodin, and Anders Osterborg
  • 31 Eposure-Response Relationship of Anticancer Agents: Perspectives from an FDA Clinical Pharmacology and Biopharmaceutics Reviewer Atiqur Rahman and Brian P. Booth
  • 32 Identifying Agents to Test in Phase III Trials Thomas G. Roberts Jr., Thomas J. Lynch Jr., and Bruce A. Chabner

「Nielsen BookData」 より

関連文献: 1件中  1-1を表示

詳細情報

ページトップへ